# AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

> **NCT07400107** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 1000 (estimated)

## Conditions studied

- Obesity
- Overweight
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** NNC0487-0111
- **DRUG:** Semaglutide
- **DRUG:** Placebo (matched to NNC0487-0111)
- **DRUG:** Placebo (matched to semaglutide)

## Key facts

- **NCT ID:** NCT07400107
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-20
- **Primary completion:** 2028-12-12
- **Final completion:** 2029-01-26
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07400107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07400107, "AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07400107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*